Published in World J Gastroenterol on September 14, 2006
Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol (2011) 1.41
Adiponectin in inflammatory and immune-mediated diseases. Cytokine (2013) 1.05
Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis. Fibrogenesis Tissue Repair (2010) 0.96
Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med (2013) 0.88
Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology (2014) 0.83
Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway. PLoS One (2013) 0.83
High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int (2008) 0.80
Adiponectin isoforms differentially affect gene expression and the lipidome of primary human hepatocytes. Metabolites (2014) 0.79
WAT is a functional adipocyte? Adipocyte (2012) 0.78
Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle (2015) 0.78
Chronic exposure to ethanol causes steatosis and inflammation in zebrafish liver. World J Hepatol (2017) 0.75
Adipokines in Liver Cirrhosis. Int J Mol Sci (2017) 0.75
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 9.79
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Blood volume in the rat. J Nucl Med (1985) 3.40
Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem (2002) 2.20
Update on nonalcoholic fatty liver disease. J Clin Gastroenterol (2002) 2.20
Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem (2004) 2.15
Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem (2005) 1.92
Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut (2005) 1.53
Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr (2004) 1.45
Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology (1996) 1.35
High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol (2005) 1.22
Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank (2003) 1.16
Cholestasis: human disease and experimental animal models. Ann Hepatol (2004) 1.12
Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis. Am J Physiol Endocrinol Metab (2004) 1.02
Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology (2004) 1.02
Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. J Hepatol (2003) 0.97
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors. Biochem Biophys Res Commun (2005) 0.95
Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol (2005) 0.88
Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonist. Eur J Pharmacol (2005) 0.87
Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes. Biochim Biophys Acta (2003) 0.84
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Adipocytokines in synovial fluid. JAMA (2003) 2.48
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2004) 2.45
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Endocrinology (2010) 2.11
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology (2008) 1.91
DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol (2011) 1.85
Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol (2006) 1.74
Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. Hepatology (2014) 1.73
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol (2010) 1.73
The potential of adiponectin in driving arthritis. J Immunol (2006) 1.70
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci (2009) 1.60
Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology (2003) 1.59
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med (2009) 1.59
Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) (2009) 1.57
Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J Gastroenterol Hepatol (2008) 1.56
Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab (2007) 1.56
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Pancreatic beta-cell growth and survival--a role in obesity-linked type 2 diabetes? Trends Mol Med (2002) 1.49
Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology (2013) 1.49
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Toxicogenomics directory of chemically exposed human hepatocytes. Arch Toxicol (2014) 1.43
CTRP family: linking immunity to metabolism. Trends Endocrinol Metab (2012) 1.38
Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res (2009) 1.38
GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets (2009) 1.34
Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol (2002) 1.34
Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology (2005) 1.34
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer (2007) 1.33
Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut (2010) 1.29
The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. Lab Invest (2008) 1.27
Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol (2003) 1.27
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Innate immunity and adipocyte function: ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemokine secretion in adipocytes. Obesity (Silver Spring) (2009) 1.24
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun (2008) 1.23
Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunol (2009) 1.22
IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol (2007) 1.21
Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res (2009) 1.20
Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis? Ann Rheum Dis (2012) 1.20
The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells. FEBS Lett (2005) 1.19
Cloning and characterization of a novel apolipoprotein A-I binding protein, AI-BP, secreted by cells of the kidney proximal tubules in response to HDL or ApoA-I. Genomics (2002) 1.18
Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol (2010) 1.18
Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology (2013) 1.18
Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum (2010) 1.17
Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol (2012) 1.17
Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis (2006) 1.15
Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism (2007) 1.14
Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep (2006) 1.14
miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J Hepatol (2012) 1.13
Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release. Biochem Biophys Res Commun (2007) 1.13
Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol (2005) 1.13
Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab (2010) 1.13
Effects of the new adiponectin paralogous protein CTRP-3 and of LPS on cytokine release from monocytes of patients with type 2 diabetes mellitus. Cytokine (2009) 1.13
Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1. FASEB J (2010) 1.13
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer (2009) 1.12
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology (2006) 1.12
Iron-induced expression of bone morphogenic protein 6 in intestinal cells is the main regulator of hepatic hepcidin expression in vivo. Gastroenterology (2009) 1.11
Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm Bowel Dis (2010) 1.11
TNFalpha is required for cholestasis-induced liver fibrosis in the mouse. Biochem Biophys Res Commun (2008) 1.11
Therapeutic management of pyoderma gangrenosum. Arthritis Rheum (2004) 1.10
Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res (2008) 1.08
Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One (2012) 1.08
Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. Int J Clin Exp Med (2010) 1.08
Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol (2009) 1.08
Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med (2005) 1.07